Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma

References

• Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311−35
   Google Scholar
• Spits-Tanin T, Grossman S, Dovrat S, et al. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrillus colocynthis on human breast cancer cells. Biochem Pharmacol 2007;73:56–67
   Google Scholar
• Lavie D, Glotter E. The cucurbitacins, a group of tetracyclic triterpenes. In: Herz W, Grisebach H, Kirby GW, eds. Progress in the chemistry of organic natural products. New York: Springer-Verlag; 1971:307–62
   Google Scholar
• Miro M. Cucurbitacins and their pharmacological effects. Phytother Res 1995;9:159–68
   Web of Science ®Google Scholar
• Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glucosides. Structure and biological activities. Nat Prod Rep 2005;22:386–99
   PubMed Web of Science ®Google Scholar
• Huang Y, de Bruyne T, Apers S, et al. Complement-inhibiting cucurbitacin glycosides from Picriea fel-terrae. J Nat Prod 1998;61:757–61
   PubMed Web of Science ®Google Scholar
• Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149–82
   PubMed Web of Science ®Google Scholar
• Petermann KB, Rozenberg GI, Zedek D, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007;12:3922–7
   Google Scholar
• Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent anti tumor activity. Oncogene 2005;24:3236–45
   PubMed Web of Science ®Google Scholar
• Bernard SA, Olayinka OA. Search for a novel antioxidant, anti-inflammatory/analgesic or anti-proliferative drug: cucurbitacins hold the ace. J Med Plants Res 2010;4:2821–6
   Google Scholar
• Bartallis J, Halaweish FT. In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines. Bioorg Med Chem 2011;19:2757–66
   Google Scholar
• Oh H, Mun Y-J, Im S-J, et al. Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med 2002;68:832–3
   PubMed Web of Science ®Google Scholar
• Chan KT, Li K, Liu SL, et al. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010;289:46–52
   PubMed Web of Science ®Google Scholar
• Blaskovich MA, Sun J, Cantor A, et al. Discover of JIS-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270–9
   PubMed Web of Science ®Google Scholar
• Fujita M, Zhu X, Sasaki K, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008;180:2089–98
   Google Scholar
• Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24:3236–45
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227–64
   PubMed Web of Science ®Google Scholar
• Horvath CM, Darnell JE. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 1997;9:233–9
   PubMed Web of Science ®Google Scholar
• Ihle JN, Kerr IM. JAKs and STATs in signaling by the cytokine receptor super family. Trends Genet 1995;11:69–74
   PubMed Web of Science ®Google Scholar
• Schindler C, Darnell, JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621–51
   PubMed Web of Science ®Google Scholar
• Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059–63
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105–15
   PubMed Web of Science ®Google Scholar
• Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606–20
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54
   PubMed Web of Science ®Google Scholar
• Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002;2:5–7
   PubMed Web of Science ®Google Scholar
• Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway in cancer drug discovery. Curr Opin Pharmacol 2005;5:350–6
   PubMed Web of Science ®Google Scholar
• Ciuffreda L, Bufalo DD, Desideri M, et al. Growth-inhibitory and antiangiogenic the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009;8:720–31
   Google Scholar
• Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7:1364–78
   PubMed Web of Science ®Google Scholar
• Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800–5
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• García-Echeverría C. Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. Purinergic Signal 2009;5:117–25
   Google Scholar
• Pollack MS, Heagney SD, Livingston PO, Fogh J. HLA-A,B,C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst 1981;66:1003–12
   PubMed Web of Science ®Google Scholar
• Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;17:6829–47
   Google Scholar